Merck & Co Inc - USD (Extended hours)Merck & Co Inc - USD (Extended hours)Merck & Co Inc - USD (Extended hours)

Merck & Co Inc - USD (Extended hours)

No trades
See on Supercharts

Key facts today

Merck & Company, Inc. secured a global license for LM-299, a bispecific antibody from LaNova Medicines, resulting in a notable pre-tax charge in Q4 and potential milestone payments.
BMO Capital downgraded Merck & Company, Inc. (MRK) from 'Outperform' to 'Market Perform' and reduced its target. Analysts still hold an average overweight rating with a mean target of $128.
Analyze the impactAnalyze the impact

See all ideas 

Displays a symbol's price movements over previous years to identify recurring trends.